One-third of all individuals with epilepsy are resistant to antiepileptic drug (AED) treatment. Antiepileptic treatment response has been suggested to be modulated by genetic polymorphisms of drug efflux transporters. Several polymorphic variants within the multidrug resistance 1 (MDR1) gene, which encodes the major transmembrane efflux transporter P-glycoprotein, have been proposed to be associated with AED resistance in epilepsy patients. The aim of this study was to evaluate the effect of C3435T and G2677T/A polymorphisms of MDR1 on AED resistance in Turkish children with epilepsy. MDR1 C3435T and G2677T/A were genotyped in 152 patients with epilepsy, classified as drug-resistant in 69 and drug-responsive in 83. Genotypes of the C3435T and G2677T/A polymorphisms were determined by polymerase chain reaction followed by restriction fragment length polymorphism. Genotype and allele frequencies of C3435T and G2677T/A polymorphisms of the MDR1 gene did not differ between drug-resistant and drug-responsive epilepsy patients. Our results suggest that MDR1 C3435T and G2677T/A polymorphisms are not associated with AED resistance in Turkish epileptic patients. To clarify the exact clinical implication of the MDR1 polymorphisms on the multidrug resistance in epilepsy, further investigations in various ethnic populations would be necessary.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877425 | PMC |
| http://dx.doi.org/10.1007/s11033-013-2866-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of ABCB1 single-nucleotide variants on early, extremely severe neutropenia induced by paclitaxel/nanoparticle albumin-bound paclitaxel in patients with gastric cancer.
Br J Clin Pharmacol
December 2024
Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
Aims: Paclitaxel and nanoparticle albumin-bound (nab)-paclitaxel can cause early, extremely severe neutropenia, occasionally leading to fatal outcomes. As paclitaxel is a substrate of P-glycoprotein, this study aimed to investigate the impact of ABCB1 single-nucleotide variants, which encode P-glycoprotein, on early, extremely severe neutropenia in patients receiving paclitaxel/nab-paclitaxel plus ramucirumab as second-line therapy for unresectable advanced/recurrent gastric cancer.
Methods: We analysed patients treated at Aichi Cancer Center Hospital from January 2018 to August 2023, with DNA samples stored in the Cancer BioBank Aichi.
ABCB1 genetic polymorphisms affect opioid requirement by altering function of the intestinal P-glycoprotein.
Biomed Pharmacother
July 2024
Department of Pain Management, China-Japan Friendship Hospital, Beijing 100029, China. Electronic address:
Article Synopsis
- The study investigates how genetic variations in the ABCB1 gene impact opioid dosage requirements in cancer patients receiving intrathecal therapy for pain relief.
- The researchers focused on specific polymorphisms (C3435T, C1236T, G2677T/A, and A61G) and found that the C3435T and G2677T/A variants significantly influenced the necessary opioid doses and the relationship between oral dosages and plasma concentrations.
- No notable differences in cerebrospinal fluid concentrations were observed between the different genotypes, suggesting that these genetic variations mainly affect opioid absorption and distribution rather than its central nervous system localization.
The association of ABCB1 gene polymorphism with clinical response to carbamazepine monotherapy in patients with epilepsy.
Mol Biol Rep
January 2024
Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
Background: Epilepsy is a common neurological disease but around 30% of patients fail to respond to antiepileptic drug (AED) treatment. Genetic variation of the ATP-binding cassette subfamily B, member 1 (ABCB1) gene, a drug efflux transporter may infer treatment resistance by decreasing gastrointestinal absorption and preventing AED entry into the brain. This study examined the impact of ABCB1 genetic variants on carbamazepine responsiveness.
View Article and Find Full Text PDFThe Interaction between Four Polymorphisms and Haplotype of , the Risk of Non-Small Cell Lung Cancer, and the Disease Phenotype.
J Oncol
January 2023
Laboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Lodz, Poland.
P-glycoprotein, product of the (ATP binding cassette subfamily B member 1) gene, has been reported to play an important role in multiple drug resistance during cancer therapy. However, its influence on non-small cell lung cancer (NSCLC) risk has not been clearly defined. The aim of the present study was to examine the association between clinicopathological factors and SNPs T-129C, C1236T, G2677T/A, and C3435T, as well as its haplotype, and to investigate the role of ABCB1 polymorphisms in NSCLC development.
View Article and Find Full Text PDFCommon SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject.
Transl Clin Pharmacol
December 2022
Department of Clinical Pharmacology and Therapeutics, Chungbuk National University College of Medicine and Hospital, Cheongju 28644, Korea.
P-glycoprotein (P-gp) is a transporter that plays an excretory role in epithelial cells. It is encoded by , and single nucleotide polymorphisms (SNPs) in this gene can affect systemic drug exposure. Dapagliflozin and sitagliptin, used in type 2 diabetes treatment, are P-gp substrates.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!